EP4698566A2 - Anticorps agonistes ciblant jaml - Google Patents

Anticorps agonistes ciblant jaml

Info

Publication number
EP4698566A2
EP4698566A2 EP24793643.8A EP24793643A EP4698566A2 EP 4698566 A2 EP4698566 A2 EP 4698566A2 EP 24793643 A EP24793643 A EP 24793643A EP 4698566 A2 EP4698566 A2 EP 4698566A2
Authority
EP
European Patent Office
Prior art keywords
antibody
antigen binding
binding fragment
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24793643.8A
Other languages
German (de)
English (en)
Inventor
Pandurangan VIJAYANAND
Christian OTTENSMEIER
Simon ESCHWEILER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
La Jolla Institute for Allergy and Immunology
Original Assignee
University of Liverpool
La Jolla Institute for Allergy and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liverpool, La Jolla Institute for Allergy and Immunology filed Critical University of Liverpool
Publication of EP4698566A2 publication Critical patent/EP4698566A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci qui se lient à une protéine de type molécule d'adhésion de jonction (JAML) ou à un fragment de celle-ci.
EP24793643.8A 2023-04-20 2024-04-19 Anticorps agonistes ciblant jaml Pending EP4698566A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363460835P 2023-04-20 2023-04-20
PCT/US2024/025560 WO2024220915A2 (fr) 2023-04-20 2024-04-19 Anticorps agonistes ciblant jaml

Publications (1)

Publication Number Publication Date
EP4698566A2 true EP4698566A2 (fr) 2026-02-25

Family

ID=93153421

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24793643.8A Pending EP4698566A2 (fr) 2023-04-20 2024-04-19 Anticorps agonistes ciblant jaml

Country Status (3)

Country Link
EP (1) EP4698566A2 (fr)
CN (1) CN121511256A (fr)
WO (1) WO2024220915A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10465005B2 (en) * 2011-08-16 2019-11-05 Emory Patent Group JAML specific binding agents, antibodies, and uses related thereto
WO2013025479A1 (fr) * 2011-08-16 2013-02-21 Emory University Agents spécifiques de liaison à jaml, anticorps, et leurs utilisations associées
WO2019237042A1 (fr) * 2018-06-08 2019-12-12 The Scripps Research Institute Ciblage d'interactions de jaml-car pour l'immunothérapie antitumorale

Also Published As

Publication number Publication date
WO2024220915A3 (fr) 2025-04-10
WO2024220915A2 (fr) 2024-10-24
CN121511256A (zh) 2026-02-10

Similar Documents

Publication Publication Date Title
US12410256B2 (en) Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
US11208498B2 (en) Treatment and prevention of cancer using HER3 antigen-binding molecules
US10662241B1 (en) HER3 antigen-binding molecules
TWI878430B (zh) 新型多肽複合物
EP2794650B1 (fr) Variants polypeptidiques fc ayant une liaison améliorée au récepteur de fc néonatal
TWI797124B (zh) 抗干擾素-γ之抗體及其應用
KR20180004125A (ko) 개질된 기능적 활성을 갖는 fc 돌연변이체
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
WO2022166977A1 (fr) Anticorps anti-il-36r humain et son application
CN116670286A (zh) 用于免疫相关疾病的人抗tigit单克隆抗体
WO2024220915A2 (fr) Anticorps agonistes ciblant jaml
CN114380917B (zh) 针对IL-17A和TNFα的双特异性单域抗体及其用途
EP4688165A1 (fr) Anticorps de liaison aux allergènes appropriés pour traiter des allergies au pollen d'arbre
JP2024540196A (ja) Ｃｃｒ２を標的とする抗体
JP2026514890A (ja) Ｊａｍｌを標的とするａｇｎｏｎｉｓｔｉｃ抗体
RU2823245C2 (ru) Антитела, нацеливающиеся на C5aR
EP4527851A1 (fr) Anticorps bispécifiques se liant à ltbr et lrrc15
WO2026017189A2 (fr) Anticorps anti-il-31, composition pharmaceutique associée et utilisation associée
CN122029195A (zh) Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
HK40061359A (en) Antibodies targeting c5ar
HK40061359B (zh) 靶向c5ar的抗体
CN112912393A (zh) 工程化的fc
HK40076302B (zh) 新型多肽复合物
HK1199270B (en) Variant fc-polypeptides with enhanced binding to the neonatal fc receptor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR